The Standard Tirzepatide Dosing Chart for Weight Loss

What Is Tirzepatide and How Does It Work?

Tirzepatide is a once-weekly injectable medication that activates two distinct hormone receptors: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). This dual-agonist mechanism sets it apart from older GLP-1-only agents. By simultaneously targeting both pathways, tirzepatide suppresses appetite more effectively, slows gastric emptying, and improves insulin sensitivity. The FDA approved it under the brand name Mounjaro for type 2 diabetes in 2022 and under the brand name Zepbound specifically for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity in late 2023. Clinical trials such as SURMOUNT-1 demonstrated average weight reductions of up to 22.5 percent of body weight at the highest maintenance dose over 72 weeks, making it one of the most effective pharmacological tools currently available for obesity treatment.

The Standard Tirzepatide Dosing Schedule

Tirzepatide dosing follows a structured escalation protocol designed to minimize gastrointestinal side effects while allowing the body to adapt to the medication. All patients begin at the lowest available dose and increase at four-week intervals. The standard escalation schedule used in clinical practice and reflected in FDA labeling is as follows:

1. Weeks 1 through 4: 2.5 mg once weekly (starting dose, not a therapeutic dose for weight loss)
2. Weeks 5 through 8: 5 mg once weekly
3. Weeks 9 through 12: 7.5 mg once weekly
4. Weeks 13 through 16: 10 mg once weekly
5. Weeks 17 through 20: 12.5 mg once weekly
6. Week 21 onward: 15 mg once weekly (maximum approved dose)

The 2.5 mg starting dose exists solely to ease the body into the medication. Prescribers and patients should understand that meaningful weight loss typically begins at the 5 mg level and accelerates at higher doses. Not every patient needs to reach 15 mg; some achieve adequate results at 10 mg or 12.5 mg and can remain at those doses indefinitely if they are well tolerated and clinically effective.

Adjusting the Dose Based on Tolerability

The four-week escalation interval is a minimum, not a strict requirement. If a patient experiences persistent nausea, vomiting, diarrhea, or constipation at a given dose, their prescriber may delay the next increase by an additional four weeks. This flexibility is built into the prescribing information because tolerability varies significantly between individuals. A slower titration does not compromise long-term outcomes; it simply extends the time before reaching a maintenance dose. Patients who miss more than two consecutive weeks of injections may need to restart the escalation process, depending on how long they were off the medication, because the body loses its adaptation to the drug relatively quickly. Any decision to restart or adjust tirzepatide dosing should be made with a licensed healthcare provider, not self-managed.

Maintenance Dosing and Long-Term Use

Once a patient reaches a dose that produces adequate weight loss with acceptable side effects, that dose becomes the maintenance dose. For many patients in clinical trials, the 10 mg and 15 mg doses produced the greatest weight reduction, but individual response curves vary. Weight loss with tirzepatide is not immediate: most patients see the most rapid reduction between months two and six, followed by a slower but continued decline through month twelve and beyond. Plateaus are common and do not necessarily indicate treatment failure. The SURMOUNT-3 and SURMOUNT-4 trials demonstrated that discontinuing the medication results in substantial weight regain, which underscores that tirzepatide is a long-term treatment rather than a short course. Prescribers typically reassess the maintenance dose at each follow-up visit, evaluating both efficacy and any emerging side effects.

Important Clinical Considerations

Contraindications

Tirzepatide carries a boxed warning for thyroid C-cell tumors based on rodent studies. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. It is also not recommended during pregnancy, as weight loss during pregnancy can harm a developing fetus. Patients with a history of pancreatitis should discuss risks carefully with their physician before starting any GIP/GLP-1 agonist.

Drug Interactions and Monitoring

Because tirzepatide slows gastric emptying, it can affect the absorption rate of oral medications taken concurrently. Patients on oral contraceptives, thyroid hormone replacement, or time-sensitive medications should inform their prescriber so that dosing timing can be adjusted if necessary. Routine monitoring typically includes periodic assessments of blood glucose, kidney function, and heart rate, particularly during the escalation phase when side effects are most pronounced. Understanding the full tirzepatide dosing picture, including not just the milligram amounts but also the timing and monitoring requirements, is essential to using this medication safely and effectively.